November 27, 2014


Boudiaf calls for 'smart', 'win-win' partnership with Germany

Minister of Health, Population and Hospital Reform, Abdelmalek Boudiaf, pleaded Wednesday in Algiers for a "smart" Algerian-German partnership in the field of health, based on the principle of "win -win."

Speaking at theopening of the first Algerian-German forum in the field of health, Boudiaf presented before the German partners, the broad lines of the modernization"...

Continue Reading >

November 27, 2014


Vargatef® (nintedanib*) approved in the EU for lung cancer patients with advanced adenocarcinoma after first-line chemotherapy

• Nintedanib*, when added to docetaxel, demonstrated over one year (12.6 months) median overall survival for advanced lung cancer patients with adenocarcinoma after first-line chemotherapy (vs. 10.3 months for patients receiving docetaxel alone)1

• The approval of nintedanib* in the European Union (EU) is primarily based on the positive results of the LUME-Lung"...

Continue Reading >

November 25, 2014


Doctors' Protest Paralyzes Hospitals

Doctors and professional workers in the health sector launched a one day protest in the majority of hospitals across the country, to condemn the policy of "ignorance" that is adopted by the ministry to consider their demands, threatening to renew it every week starting from the coming December.

Algerian hospitals noticed an almost complete paralysis in patients' care, as the majority of workers, general practitioners and specialists"...

Continue Reading >

November 25, 2014


New Data from a Pooled Analysis Shows Improved Overall Survival for Prostate Cancer Patients Treated With FIRMAGON® (Degarelix) Compared To LHRH Agonists

New data published in the December issue of the European Journal of Urology indicates improvement in overall survival (OS) and prostate specific antigen progression free survival (PSA PFS) for degarelix (FIRMAGON®), a gonadotropin releasing hormone (GnRH) antagonist, compared to commonly prescribed luteinising hormone-releasing hormone (LHRH) agonists. In addition, the data showed a reduction in the incidence of joint, musculoskeletal and urinary tract adverse events for those men with prostate cancer treated with degarelix"...

Continue Reading >

November 24, 2014


Nintedanib* receives positive CHMP opinion in European Union for the treatment of IPF

• Phase III INPULSIS® trials showed that nintedanib* slows disease progression in a broad range of IPF patient types** with a 50% reduction in the decline of lung function

• Nintedanib* significantly reduced the risk of adjudicated acute exacerbations‡ by 68%

• Positive opinion follows the recent FDA approval of nintedanib* for the treatment of patients with"...

Continue Reading >

November 23, 2014


Cancer plan to be submitted to President Bouteflika in next few days, Dr. Bouzid says

The national plan of action against cancer 2015-2019 has been finalized and will be submitted in the next few days to President of the Republic, Abdelaziz Bouteflika, head of oncology services at Pierre and Marie Curie Centre (CPMC), Dr Kamel Bouzid said Friday in Algiers.

"Dr. Messaoud Zitouni, appointed by the President to implement the cancer plan, will submit in"...

Continue Reading >

November 21, 2014


Phyathai Nawamin International Hospital Thailand Now Offers Spinal Surgery with Advanced Technology of Decompression

Phyathai Nawamin International Hospital’s Spine and Brain Center now offers the newest and updated medical treatment technique for Spinal Surgery with Advanced Technology of Decompression, supported by Phyathai Group of hospitals, an established name as a leading health care provider in the Kingdom of Thailand.


Continue Reading >

November 19, 2014


New data show dabigatran-specific antidote idarucizumab* restores blood clotting mechanism in humans

  • Idarucizumab, which was granted Breakthrough Therapy Designation by the FDA, was shown to restore the blood clotting mechanism in healthy volunteers1,2
  • This is the first time that such an effect was shown in humans for a NOAC antidote
  • RE-VERSE AD™ Global Phase III study in patients in the clinical setting already initiated in 29 countries worldwide3

For Non-US/Non-UK/Non-Canadian Media


Continue Reading >

November 19, 2014


Two new, large scale real-world analyses show fewer major bleeds and strokes with Pradaxa® than with warfarin

  • American Heart Association’s Scientific Sessions 2014: Latest real-world data once again reinforce benefits from Pradaxa®1,2
  • Two new analyses involving over 60,000 US patients in total show that Pradaxa® was linked to fewer major bleeds and strokes than warfarin1,2
  • Results shown in RE-LY® clinical study supported by data from different patient populations in general practice1-4

For Non-US/Non-UK/Non-Canadian Media


Continue Reading >

November 19, 2014


Oral OTEZLA® (Apremilast) Showed Sustained Clinical Response over Two Years in Patients with Active Psoriatic Arthritis

ACR 20 response rates sustained with continued OTEZLA treatment through 104 weeks - 65.3 percent and 61.4 percent in PALACE 1 and 4, respectively

Eighty four percent of patients who completed one year of treatment with OTEZLA continued on OTEZLA through week 104 in both trials

The rates of most commonly reported adverse events of diarrhea, nausea and headache decreased during"...

Continue Reading >